Antitumor activity of Z15-0-2, a bispecific nanobody targeting PD-1 and CTLA-4
Open Access
- 28 May 2024
- journal article
- research article
- Published by Springer Nature in Oncogene
- Vol. 43 (29) , 2244-2252
Abstract
The combination of programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) antibodies has potential for enhancing clinical efficacy. We described the development and antitumor activity of Z15-0, a bispecific nanobody targeting both the PD-1 and CTLA-4 pathways simultaneously. We designed and optimized the mRNA sequence encoding Z15-0, referred to as Z15-0-2 and through a series of in vitro and in vivo experiments, we established that the optimized Z15-0-2 mRNA sequence significantly increased the expression of the bispecific nanobody. Administration of Z15-0-2 mRNA to tumor-bearing mice led to greater inhibition of tumor growth compared to controls. In aggregate, we introduced a novel bispecific nanobody and have re-engineered it to boost expression of mRNA, representing a new drug development paradigm.Keywords
This publication has 36 references indexed in Scilit:
- Myeloid-derived suppressor cells as regulators of the immune systemNature Reviews Immunology, 2009
- Structural characterization of a human Fc fragment engineered for lack of effector functionsActa Crystallographica Section D Structural Biology, 2008
- Characterization of the ribonuclease activity on the skin surfaceGenetic Vaccines and Therapy, 2006
- Emergence and evolution of functional heavy-chain antibodies in CamelidaeDevelopmental & Comparative Immunology, 2003
- Three-Dimensional Structure of the Complex between a T Cell Receptor β Chain and the Superantigen Staphylococcal Enterotoxin BImmunity, 1998
- Binary and ternary complexes between T-cell receptor, class II MHC and superantigen in vitroNature, 1994
- Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigenNature, 1994
- Naturally occurring antibodies devoid of light chainsNature, 1993
- Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity.Proceedings of the National Academy of Sciences, 1988
- Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies.Journal of Experimental Medicine, 1987